AI Article Synopsis
- Patients with blood cancers and a history of hepatitis B face a risk of the virus reactivating, especially when treated with the drug ruxolitinib, which is used for myeloproliferative neoplasms.
- Despite the moderate reactivation risk (1-10%) during ruxolitinib treatment, there are no strong guidelines for HBV prevention in these patients.
- The report details a case of a patient with primary myelofibrosis who experienced HBV reactivation after stopping their preventive medication, highlighting the need for ongoing HBV protection when using ruxolitinib.
Article Abstract
Patients with hematological malignancies and past serological evidence of hepatitis B are at risk for HBV reactivation. In myeloproliferative neoplasms, continuous treatment with the JAK 1/2 inhibitor ruxolitinib confers a moderate risk of reactivation (1-10%); nevertheless, no prospective randomized data are available to strongly recommend HBV prophylaxis in these patients. Here, we report a case of primary myelofibrosis and past serological evidence of HBV infection, treated with ruxolitinib and concomitant lamivudine, developing HBV reactivation due to premature withdrawal of prophylaxis. This case underlines the potential need for persistent HBV prophylaxis in the setting of ruxolitinib treatment.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183604 | PMC |
| http://dx.doi.org/10.3389/fonc.2023.1163175 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!